Name: KALARIS THERAPEUTICS INC (KLRS) Stock
Brand: KALARIS THERAPEUTICS INC
Rating: 6 (3 reviews)

KLRS Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill - Mentions: INSM BEAT NINE ASNS ...

Wondering what's happening in today's after-hours session?

a day ago - By: Chartmill - Mentions: PLCE SPIR DBVT YCBD ...

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

a day ago - By: Kalaris Therapeutics, Inc.

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

a day ago - By: Kalaris Therapeutics, Inc.

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

a month ago - By: Benzinga - Mentions: DERM INTS LPTX CMND ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a month ago - By: Kalaris Therapeutics, Inc.

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: Kalaris Therapeutics, Inc.

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

2 months ago - By: Benzinga - Mentions: ONMD RLMD AQB LPTX ...

12 Health Care Stocks Moving In Monday's Intraday Session

3 months ago - By: Kalaris Therapeutics, Inc.

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

4 months ago - By: Zacks Investment Research

Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know

4 months ago - By: The Motley Fool

Kalaris Reports Loss Cash at 88 Million

4 months ago - By: Kalaris Therapeutics, Inc.

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

7 months ago - By: Kalaris Therapeutics, Inc.

Kalaris to Participate at Stifel Ophthalmology Forum